Clinical Judgment Versus Biomarker Prostate Cancer Gene 3: Which Is Best When Determining the Need for Repeat Prostate Biopsy?Bertrand Tombal, Herman Stoevelaar, Louis Smets et al.|Urology|2013Cited by 32
Risk factors for disease progression in patients with lower urinary tract symptoms/benign prostatic hyperplasia (LUTS/BPH): a systematic analysis of expert opinionFranklin C. Lowe, Herman Stoevelaar, J.E. Batista et al.|Prostate Cancer and Prostatic Diseases|2005Cited by 29
Impact of adoption of a decision algorithm including PCA3 for repeat biopsy on the costs for prostate cancer diagnosis in FranceBernard Malavaud, Herman Stoevelaar, Olivier Cussenot et al.|Journal of Medical Economics|2012Cited by 15
Integrating risk profiles for disease progression in the treatment choice for patients with lower urinary tract symptoms/benign prostatic hyperplasia: a combined analysis of external evidence and clinical expertiseMark Speakman, Herman Stoevelaar, J.E. Batista et al.|Prostate Cancer and Prostatic Diseases|2005Cited by 13
Gastro‐protective treatment in patients using NSAIDsDevelopment of appropriateness criteria by a multidisciplinary expert panelHerman Stoevelaar, J. McDonnell, H Stals et al.|Scandinavian Journal of Rheumatology|2003Cited by 7